Aldeyra's Dry Eye Disease Trial Meets Primary Endpoint, But Misses On Secondary Endpoint

Aldeyra Therapeutics Inc's ALDX reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease.
The ocular redness scores in the reproxalap group were statistically lower than those of vehicle.
Mean visual analog scale ocular dryness and discomfort scores were lower in reproxalap-treated subjects than in vehicle-treated subjects. However, differences did not reach statistical significance.
Tear RASP level results from the trial are expected to be available later this quarter.
No safety or tolerability concerns were observed in the trial.
The most common adverse event was mild and transient instillation site discomfort lasting less than one minute, similar to many prescribed topical ophthalmic medications.
Two Phase 3 trials of reproxalap in patients with dry eye disease, TRANQUILITY, and TRANQUILITY-2, are ongoing.
For each trial, the planned enrollment is 300 patients, and the primary endpoint is ocular redness.
Results from the TRANQUILITY trials are expected to be released by the end of the year.
Price Action: ALDX shares are down 9.42% at $8.37 during the market session on the last check Tuesday.